189 related articles for article (PubMed ID: 34708886)
21. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
[TBL] [Abstract][Full Text] [Related]
22. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
Abdeen S; Abu-Fanne R; Bdeir K; Maraga E; Higazi M; Cines DB; Heyman SN; Higazi AA
Br J Haematol; 2022 Feb; 196(4):923-927. PubMed ID: 34622440
[TBL] [Abstract][Full Text] [Related]
23. Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.
Elshafei MN; El-Bardissy A; Khalil A; Danjuma M; Mubasher M; Abubeker IY; Mohamed MFH
Eur J Clin Invest; 2021 Sep; 51(9):e13645. PubMed ID: 34185313
[TBL] [Abstract][Full Text] [Related]
24. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients : A meta-analysis.
Nugroho J; Wardhana A; Maghfirah I; Mulia EPB; Rachmi DA; A'yun MQ; Septianda I
Int J Lab Hematol; 2021 Feb; 43(1):110-115. PubMed ID: 32931146
[TBL] [Abstract][Full Text] [Related]
25. D-dimer levels and COVID-19 severity: Systematic Review and Meta-Analysis.
Düz ME; Balcı A; Menekşe E
Tuberk Toraks; 2020 Dec; 68(4):353-360. PubMed ID: 33448732
[TBL] [Abstract][Full Text] [Related]
26. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
[TBL] [Abstract][Full Text] [Related]
27. The Efficacy of Colchicine as an Adjunct Therapy in Non-hospitalized COVID-19 Patients: A Randomized Placebo-Controlled Trial.
Hejazi S; Jahani Z; Elyasi S; Salarbashi D; Kabiri M
Recent Adv Antiinfect Drug Discov; 2024; 19(3):254-263. PubMed ID: 37711106
[TBL] [Abstract][Full Text] [Related]
28. Impact of colchicine on mortality and morbidity in COVID-19: a systematic review.
Sanghavi D; Bansal P; Kaur IP; Mughal MS; Keshavamurthy C; Cusick A; Schram J; Yarrarapu SNS; Giri AR; Kaur N; Moreno Franco P; Abril A; Aslam F
Ann Med; 2022 Dec; 54(1):775-789. PubMed ID: 35258357
[TBL] [Abstract][Full Text] [Related]
29. Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.
Ghayda RA; Lee J; Lee JY; Kim DK; Lee KH; Hong SH; Han YJ; Kim JS; Yang JW; Kronbichler A; Smith L; Koyanagi A; Jacob L; Shin JI
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32668763
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.
Melo AKG; Milby KM; Caparroz ALMA; Pinto ACPN; Santos RRP; Rocha AP; Ferreira GA; Souza VA; Valadares LDA; Vieira RMRA; Pileggi GS; Trevisani VFM
PLoS One; 2021; 16(6):e0253894. PubMed ID: 34185801
[TBL] [Abstract][Full Text] [Related]
31. Analyzing Correlation of Clinical Severity of COVID-19 with Other Biochemical Parameters: A Retrospective Study from Pakistan.
Hassan Shah SST; Naeem I; Wahid B
Tohoku J Exp Med; 2021 Dec; 255(4):315-323. PubMed ID: 34911879
[TBL] [Abstract][Full Text] [Related]
32. Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.
Farid E; Sridharan K; Alsegai OA; Khawaja SA; Mansoor EJ; Teraifi NA; Qahtani MA; Salman JA
Biomark Med; 2021 Jun; 15(8):541-549. PubMed ID: 33988463
[No Abstract] [Full Text] [Related]
33. Discrepancy between biomarkers of lung injury and 1-year mortality in COVID-19.
Atalay B; Cesur A; Agirbasli M
Eur J Clin Invest; 2022 Sep; 52(9):e13827. PubMed ID: 35753029
[TBL] [Abstract][Full Text] [Related]
34. Routine laboratory testing to determine if a patient has COVID-19.
Stegeman I; Ochodo EA; Guleid F; Holtman GA; Yang B; Davenport C; Deeks JJ; Dinnes J; Dittrich S; Emperador D; Hooft L; Spijker R; Takwoingi Y; Van den Bruel A; Wang J; Langendam M; Verbakel JY; Leeflang MM;
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013787. PubMed ID: 33211319
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of COVID-19: Changes in laboratory parameters.
Lagadinou M; Salomou EE; Zareifopoulos N; Marangos M; Gogos C; Velissaris D
Infez Med; 2020 Jun; 28(suppl 1):89-95. PubMed ID: 32532944
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of colchicine in the treatment of acute myocardial infarction: A protocol for systematic review and meta-analysis.
Xiong H; Huang X; Rao L; Zhao J
Medicine (Baltimore); 2021 Apr; 100(14):e25429. PubMed ID: 33832144
[TBL] [Abstract][Full Text] [Related]
37. Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.
Khinda J; Janjua NZ; Cheng S; van den Heuvel ER; Bhatti P; Darvishian M
J Med Virol; 2021 Feb; 93(2):1078-1098. PubMed ID: 32776551
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.
Huang I; Pranata R; Lim MA; Oehadian A; Alisjahbana B
Ther Adv Respir Dis; 2020; 14():1753466620937175. PubMed ID: 32615866
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial.
Rahman M; Datta PK; Islam K; Haque M; Mahmud R; Mallik U; Hasan P; Haque M; Faruq I; Sharif M; Ratul RH; Azad KAK; Miah T; Rahman MM
PLoS One; 2022; 17(11):e0277790. PubMed ID: 36383611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
